Immuron Commences Travelan Clinical Study Cohort 2 for Prevention of Infectious Diarrhea by Enterotoxigenic Escherichia Coli (ETEC)
Portfolio Pulse from Benzinga Newsdesk
Immuron Limited has commenced the second cohort of a clinical trial to evaluate the efficacy of Travelan for the prevention of infectious diarrhea caused by enterotoxigenic Escherichia coli. The study is being led by Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit in Baltimore, Maryland US.
October 18, 2023 | 10:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immuron's commencement of the second cohort of the Travelan clinical trial could potentially boost investor confidence in the company's product pipeline.
The progression of a clinical trial to its next phase is generally seen as a positive development, indicating that the drug has passed previous safety and efficacy checks. This could potentially boost investor confidence in Immuron's product pipeline, leading to a positive impact on the company's stock.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100